Diabetic papillopathy. Patient characteristics and fundus findings
- PMID: 7605280
- DOI: 10.1001/archopht.1995.01100070063026
Diabetic papillopathy. Patient characteristics and fundus findings
Abstract
Objective: To better define the spectrum of patient characteristics and fundus findings in patients with a presumably unique clinical entity referred to as diabetic papillopathy.
Design: Retrospective series.
Setting: A university-based referral practice.
Methods: We retrospectively reviewed the medical records of all diabetic patients with benign, transient disc swelling who were evaluated at our institution from 1986 to 1992. Data pertaining to patient demographics, visual acuity and symptoms, disc and retinal findings, ancillary test results, and clinical course were collected.
Results: Twenty-seven eyes of 19 patients met the study definition of diabetic papillopathy. Patients were generally older (mean age, 50 years) and of a broader age range (19 to 79 years) compared with those in prior reports. Two thirds of patients had type II diabetes. Disc swelling was consistently hyperemic and, on average, resolved within 3.7 months. Macular edema was a frequent associated finding (70% of eyes) as was significant capillary nonperfusion (52% of tested eyes). Only four eyes (15%) had final visual acuities of less than 20/50 and each had prominent macular edema. Cup-disc ratio analysis of uninvolved eyes revealed a significantly small physiologic cup.
Conclusions: The clinical profile of diabetic papillopathy can be expanded to include people who are older or have type II diabetes and that affected eyes commonly have macular edema or retinal vascular changes that can adversely affect the visual outcome. Last, a small physiologic cup may represent an anatomic predisposition to the condition.
Similar articles
-
Diabetic papillopathy in type II diabetic patients.Retina. 2002 Dec;22(6):752-8. doi: 10.1097/00006982-200212000-00011. Retina. 2002. PMID: 12476102
-
Diabetic papillopathy: two case reports in individuals with adult onset diabetes mellitus.J Am Optom Assoc. 1997 Sep;68(9):595-603. J Am Optom Assoc. 1997. PMID: 9308304
-
Diabetic papillopathy and proliferative retinopathy.Graefes Arch Clin Exp Ophthalmol. 1986;224(1):46-50. doi: 10.1007/BF02144133. Graefes Arch Clin Exp Ophthalmol. 1986. PMID: 2417914
-
Diabetic papillopathy: current and new treatment options.Curr Diabetes Rev. 2011 May;7(3):171-5. doi: 10.2174/157339911795843122. Curr Diabetes Rev. 2011. PMID: 21418004 Review.
-
Diabetic papillopathy and its relation to optic nerve ischemia.Optom Vis Sci. 2009 Apr;86(4):e395-403. doi: 10.1097/OPX.0b013e318198927c. Optom Vis Sci. 2009. PMID: 19225435 Review.
Cited by
-
Diabetic papillopathy with macular edema treated with intravitreal bevacizumab.Oman J Ophthalmol. 2011 Sep;4(3):135-8. doi: 10.4103/0974-620X.91270. Oman J Ophthalmol. 2011. PMID: 22279402 Free PMC article.
-
The optic nerve head in acquired optic neuropathies.Nat Rev Neurol. 2010 Apr;6(4):221-36. doi: 10.1038/nrneurol.2010.5. Epub 2010 Mar 9. Nat Rev Neurol. 2010. PMID: 20212512 Review.
-
Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.J Med Case Rep. 2021 Oct 22;15(1):518. doi: 10.1186/s13256-021-03129-1. J Med Case Rep. 2021. PMID: 34674724 Free PMC article.
-
Ocular complications of diabetes mellitus.World J Diabetes. 2015 Feb 15;6(1):92-108. doi: 10.4239/wjd.v6.i1.92. World J Diabetes. 2015. PMID: 25685281 Free PMC article. Review.
-
Response of diabetic papillopathy to intravitreal bevacizumab.Middle East Afr J Ophthalmol. 2011 Jul;18(3):243-5. doi: 10.4103/0974-9233.84056. Middle East Afr J Ophthalmol. 2011. PMID: 21887082 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous